vimarsana.com

Page 144 - அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

What Drives the Clinical Benefits Seen with SGLT2 Inhibitors?

Feb 5, 2021 Volume, volume, volume may be the answer As findings from trial after trial provide evidence of the clinical benefit of SGLT2 inhibition in patients with reduced ejection fraction heart failure (HFrEF) DAPA-HF, EMPIRE-HF, EMPEROR-Reduced, there is little convincing left to do about the value of adding SGLT2 inhibitors to the HF armamentarium, as demonstrated by their inclusion in an updated expert decision pathway issued by the American College of Cardiology in early January 2021. But exactly why these drugs provide these demonstrable benefits is still debatable. Jesper Jensen, MD, PhD, of Herlev and Gentofte University Hospital, Herlev, Denmark, and University of Copenhagen, Copenhagen, Denmark, and colleagues drilled down into data from a prespecified substudy of EMPIRE-HF (EMPIRE-HF Renal) to investigate the “effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate (GFR) in patients with hear

Transcatheter Aortic Valve Replacement/Implantation Market Expected To Rise By 2026, Estimates DelveInsight

In November 2020, Boston Scientific Corp. announced the immediate retirement of the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. In October 2020, Medtronic announced that it will begin a randomized, head-to-head study comparing two transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic stenosis (ssAS). In August 2019, Medtronic plc received U.S. Food and Drug Administration (FDA) approval for the indication expansion of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at low risk of surgical mortality. Request for Sample @ Transcatheter Aortic Valve Replacement Market Analysis Transcatheter Aortic Valve Replacement (TAVR), also known as Transcatheter Aortic Valve Implantation (TAVI), is a minimally invasive surgery performed to insert a new valve without removing the damaged one (aortic valve stenosis). Generally, a va

Less invasive TAVR surgery improves patient s quality of life

Bicuspid Aortic TAVR May Create Huge Market For Transcatheter Valves

Bicuspid Aortic TAVR May Create Huge Market For Transcatheter Valves February 4, 2021 Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the patients with bicuspid valve valves, but recent studies may soon open the door to wider use of TAVR in this population. “Physicians have previously been cautious about using TAVR in patients with bicuspid valve stenosis due to a number of factors, explained Ashley Young, senior medical devices analyst at GlobalData healthcare market research. Perhaps most importantly, the long-term durability of TAVR valves has yet to be thoroughly proven in a robust clinical trial setting. This is of utmost importance to patients with bicuspid aortic valve anatomy, who typically present with stenosis at a younger age and depend on long-term durability of replacement valves.”

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.